cevipabulin
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2005 (NCT00195247)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tubulin betaINHIBITOR
Tubulin beta inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
- Tubulin beta-8 chain-like protein LOC260334 (TUBB8B) ↗
Chemistry & pharmacology
Loading structure…
SMILES
CNCCCOc1cc(F)c(-c2c(Cl)nc3ncnn3c2N[C@@H](C)C(F)(F)F)c(F)c1- Mol. weight
- 464.83 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1182714 ↗
Also known as
- 5-chloro-6-(2,6-difluoro-4-(3-(methylamino)propoxy)phenyl)-n-(1,1,1-trifluoropropan-2-yl)-(1,2,4)triazolo(1,5-a)pyrimidin-7-amine
- cevipabulin
- cevipabulin
- cevipabulin
- cndr-51533
- cndr-51657
- tti-237
- tti-237
- tti-237
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00195325 | Phase 1 | Aug 1, 2005 | Pfizer, Wyeth |
| NCT00195247 | Phase 1 | May 1, 2005 | Pfizer, Wyeth |
Showing 2 of 2 trials
Page 1 / 1